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BACKGROUND: To the authors’ knowledge, studies regarding risk perception among survivors of thyroid cancer are scarce. METHODS: 
The authors surveyed patients who were diagnosed with differentiated thyroid cancer from the Surveillance, Epidemiology, and End 
Results registries of Georgia and Los Angeles County (2632 patients; 63% response rate). The analytic cohort was defined by a ≤5% risk 
of disease recurrence and mortality (1597 patients). Patients estimated their recurrence and mortality risks separately (increments of 10% 
and endpoints of ≤5% and ≥95%). Both outcomes were dichotomized between reasonably accurate estimates (risk perception of ≤5% or 
10%) versus overestimation (risk perception of ≥20%). Multivariable logistic regression was used to identify factors associated with risk 
overestimation, and the relationships between overestimation and both worry and quality of life were evaluated. RESULTS: In the current 
study sample, 24.7% of patients overestimated their recurrence risk and 12.5% overestimated their mortality risk. A lower educational 
level was associated with overestimating disease recurrence (≤high school diploma: odds ratio [OR], 1.64 [95% CI, 1.16-2.31]; and some 
college: OR, 1.36 [95% CI, 1.02-1.81]) and mortality (≤high school diploma: OR, 1.86 [95% CI, 1.18-2.93]) risk compared with those attaining 
at least a college degree. Hispanic ethnicity was found to be associated with overestimating recurrence risk (OR, 1.44, 95% CI 1.02-2.03) 
compared with their white counterparts. Worry about recurrence and death was found to be greater among patients who overestimated 
versus those who had a reasonably accurate estimate of their risk of disease recurrence and mortality, respectively (P < .001). Patients 
who overestimated mortality risk also reported a decreased physical quality of life (mean T score, 43.1; 95% CI, 41.6-44.7) compared with 
the general population. CONCLUSIONS: Less educated patients and Hispanic patients were more likely to report inaccurate risk percep-
tions, which were associated with worry and a decreased quality of life. Cancer 2020;126:1512-1521. © 2019 American Cancer Society. 
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INTRODUCTION
The majority of patients with differentiated thyroid cancer (DTC) have low-risk disease.1-4 Despite having an excellent 
prognosis, prior work has shown that patient worry regarding disease recurrence and death is common, with underrepre-
sented minority groups especially at risk.5 In addition, there are conflicting data concerning patient quality of life (QOL), 
with some studies finding that patients with thyroid cancer have a worse QOL compared with those with melanoma, 
colorectal cancer, and the general population, and other studies reporting that their QOL is similar to that of healthy 
patients without cancer.6-9 To the best of our knowledge, the reasons for the discordance between patient prognosis and 
patient worry and QOL remain unknown.
Although studies regarding disease recurrence and mortality risk perception among patients with thyroid cancer are 
lacking, it is plausible that inaccurate risk estimates by patients might contribute to persistent cancer-related worry and 
poor QOL. In particular, to our knowledge, there is little information regarding which survivors of thyroid cancer with 
a favorable prognosis are at risk of overestimating their risk of recurrence and death. The identification of survivors of 
thyroid cancer who are vulnerable to inaccurate risk perceptions is needed to effectively tailor risk communication and 
patient education.
The goal of the current study was to determine the level of perceived risk of disease recurrence and of mortality from 
thyroid cancer among low-risk patients. We hypothesized that overestimation of recurrence and mortality risk would be 
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associated with both increased cancer-related worry and 
decreased QOL.
MATERIALS AND METHODS
Study Population and Data Collection
Between February 1, 2017, and October 31, 2018, we 
conducted a large, cross-sectional, population-based sur-
vey of patients aged 18 to 79 years who were diagnosed 
with DTC between January 1, 2014, and December 
31, 2015. Patients were sampled from the Surveillance, 
Epidemiology, and End Results (SEER) registries of 
Georgia and Los Angeles County. To improve response 
rates, a modified Dillman method was used, which con-
sisted of a $20 cash incentive included with the initial 
mailing, contact tracing, follow-up telephone calls, and 
multiple mailings to nonresponders.10 Patients with 
Spanish surnames were mailed surveys in both English 
and Spanish, and bilingual interviewers conducted follow-
up telephone calls. Survey data were entered electronically 
using a double entry method to ensure <1% error. Survey 
responses were merged with clinical cancer data from the 
respective SEER registries to create a deidentified data 
set. The study was approved by the institutional review 
boards of the University of Michigan, the University of 
Southern California, Emory University, the California 
Committee for the Protection of Human Subjects, the 
California Cancer Registry, and the Georgia Department 
of Public Health.
Of the 4317 patients identified and mailed a survey, 
a total of 4185 were determined to be eligible. A total 
of 2632 patients responded, yielding a 63% response 
rate, calculated as the number of respondents divided by 
eligible patients, and a 77% cooperation rate, calculated 
as the number of respondents divided by all patients 
who were able to be contacted.11 For these analyses, we 
restricted the analytic sample to low-risk patients with 
both a clinically determined ≤5% risk of persistent struc-
tural or recurrent thyroid cancer and a 10-year mortal-
ity risk ≤5% (1597 patients) (Fig. 1). All patients in the 
analytic sample had intrathyroidal classic papillary or 
follicular thyroid carcinoma with no evidence of lymph 
node or distant metastases.
To determine patients’ clinical 10-year risk of 
persistent structural or recurrent thyroid cancer, we 
adapted information from the 2015 American Thyroid 
Association risk stratification system and findings by 
Tuttle et al regarding recurrence risk estimates in patients 
with DTC.1,12 We defined such risk to be ≤5% in patients 
with an intrathyroidal papillary or follicular thyroid can-
cer measuring ≤4 cm with no evidence of lymph node 
or distant metastases. We excluded patients whose risk of 
persistent structural or recurrent thyroid cancer was >5% 
(992 patients) or unknown (43 patients). This exclusion 
category included patients with more aggressive variants 
of papillary or follicular thyroid cancers because their 
risk of disease recurrence would be higher. These aggres-
sive variants were identified using the following SEER 
International Classification of Diseases for Oncology, Third 
Edition (ICD-O-3) morphology codes for thyroid cancer 
diagnosis: 8290 (Hurthle cell cancer), 8332 (trabecular 
follicular thyroid cancer), 8337 (insular cancer), and 
8344 (columnar cell variant of papillary thyroid cancer).
Patients’ clinical 10-year mortality risk was 
determined using age at the time of diagnosis and SEER 
Summary Stage to assign individuals to 1 of 4 distinct 
prognostic groups identified by Banerjee et al in their 
study of 43,392 patients with well-differentiated thyroid 
cancer using SEER data.2,13 Mortality risk was defined as 
≤5% in patients of any age with localized disease or those 
aged ≤63 years with regional disease.
Measures
The survey instrument was developed based on the 
research questions and hypotheses, a systematic review of 
the literature, and prior work in other low-risk cancers 
(see Supporting Materials).1,2,12,14-18 We used standard 
techniques to assess content validity, including review by 
design experts, content experts, and experts in risk per-
ception, and pilot testing in a selected cohort of patients 
at the University of Michigan.
Patient Perceptions Regarding Disease 
Recurrence and Mortality Risk From 
Thyroid Cancer
Patients were asked to “Imagine 100 patients with the 
same size and type of thyroid cancer as you” followed 
by “How many of these patients do you think will have 
their thyroid cancer come back within the next 10 years 
(that is have cancer recurrence)?” and “How many of 
these patients do you think will die in the next 10 years?” 
Response categories for both questions were based on an 
11-point scale with increments of 10 and endpoints of 
≤5 and ≥95. For the analysis, we converted responses 
into percentages (11-point scale: increments of 10% and 
endpoints of ≤5% and ≥95%). Using categories similar 
to those in breast cancer studies conducted by members 
of our team to assess risk estimation, we categorized the 
outcomes into 2 groups: reasonably accurate estimate 
(risk perception of ≤5% or 10%) versus overestimation 
(risk perception of 20% to ≥95%) of disease recurrence 
and mortality risk in this analytic sample of patients with 
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clinically determined 10-year recurrence and mortality 
risks of ≤5%.14,19
Patient Report of Worry
To determine worry regarding disease recurrence and death 
from thyroid cancer, we adapted questions from worry 
scales used in the breast cancer literature.15-17 Patients were 
asked to rate how much they worried about “thyroid can-
cer coming back” and “death from thyroid cancer” within 
the past month. A 5-point Likert scale with the following 
response categories was used: 1) not at all; 2) a little; 
3) somewhat; 4) quite a bit; and 5) very much. For the 
analysis, we defined patient-reported “worry” as those who 
worried somewhat, quite a bit, or very much. This categori-
zation was used to identify those patients who had a degree 
of worry that potentially could influence health behaviors.
Patient Report of QOL
The Patient-Reported Outcomes Measurement 
Information System (PROMIS) Global Health ques-
tionnaire (version 1.2), which is based on item response 
theory, was used to measure QOL.18 Physical and men-
tal health raw scores were summed and converted into 
T scores, which were normalized to a sample population 
that represented the 2000 general US population with a 
mean of 50 and a standard deviation of 10. Accurate con-
version to T scores requires the completion of all 4 items 
for each subscale, and therefore we excluded patients who 
did not respond to all the required items (38 patients for 
physical QOL and 38 patients for mental QOL). Higher 
scores indicated better outcomes such that higher physical 
QOL scores indicated better physical function.
Covariates
We obtained the following demographic characteris-
tics from the survey: sex (female vs male), race/ethnicity 
(Hispanic, black, white, or other), and highest level of 
education attained (≤high school diploma, some col-
lege, and ≥college degree). With regard to race/ethnicity, 
patients were asked to check all options that best described 
their race/ethnicity. Similar to prior studies, patients who 
selected multiple options for race/ethnicity were assigned 
to 1 category according to the following priority order: 
Hispanic, black, white, and other.5,20 Each individual 
was analyzed as having 1 race/ethnicity. Clinical cancer 
characteristics obtained from the SEER registries were age 
Figure 1. Flow diagram demonstrating analytic sample selection. The response rate was 63% and the cooperation rate was 77%. 
LA indicates Los Angeles County; SEER, Surveillance, Epidemiology, and End Results program.
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at the time of diagnosis (in years), ICD-O-3 morphol-
ogy codes for thyroid cancer diagnosis, and the tumor 
size and extension from both the clinical and pathologic 
sources that the SEER registries used to derive a T clas-
sification following definitions from the American Joint 
Committee on Cancer seventh edition staging system.21
Statistical Analyses
Descriptive statistics were generated for all categorical 
variables, and we have reported nonweighted frequencies 
and weighted percentages. We used multivariable logistic 
regression analysis to determine factors associated with 
the overestimation of recurrence risk and of mortality 
risk. We reported adjusted odds ratios (ORs) with 95% 
CIs for all logistic regression models, with P values <.05 
considered to be statistically significant.
Rao-Scott adjusted chi-square tests were used to test 
for a relationship between patients’ perception of risk of 
disease recurrence and mortality risk (reasonably accurate 
estimate or overestimate) and worry about recurrence and 
death, respectively.
We compared between-group mean physical and 
mental health T scores of the analytic sample, grouped 
by patients’ perceived risk (reasonably accurate estimate 
or overestimate) of recurrence and of mortality, using a 
regression analysis to the general US population. A mean-
ingful change in global physical or mental health was de-
fined as a minimal difference of approximately one-half 
of an SD, or 5 points, compared with the mean for the 
sample population that represented the 2000 general US 
Census (mean T score, 50).18
All statistical analyses incorporated weights to 
account for differential sampling and to reduce potential 
nonresponse bias. This included the use of design weights 
to account for differential probability of sample selection 
and nonresponse weights to account for disproportionate 
nonresponse rates across different patient subgroups. This 
weighting aims to generate statistical inferences that are 
more representative of the target population.22,23 The per-
centages and ORs reported were weighted and the num-
ber of participants, when provided, was unweighted for 
clarity. Analyses were performed using STATA (version 
15.1; StataCorp LLC, College Station, Texas), R (version 
3.5.2; R Foundation for Statistical Computing, Vienna, 
Austria), and SAS (version 9.4; SAS Institute Inc, Cary, 
North Carolina) statistical software.
RESULTS
Table 1 provides the distribution of patient demographics, 
tumor characteristics, and risk perception of the study 
sample. Of the 1597 low-risk patients in the sample, 1285 
(80.9%) were female, 997 (58.5%) were white, and 719 
(45.9%) had at least a college degree. The majority had T1a 
(52.5%) or T1b (26.7%) disease at the time of diagnosis. 
Approximately one-quarter of the sample (24.7%) overes-
timated their 10-year recurrence risk from thyroid cancer, 
and 12.5% overestimated their 10-year mortality risk.
Figures 2 and 3 show the multivariable adjusted 
ORs and 95% CIs of correlates of overestimation of dis-
ease recurrence and mortality risk, respectively. A lower 
educational level was associated with the overestimation 
of both risk of disease recurrence (≤high school diploma: 
OR, 1.64 [95% CI, 1.16-2.31]; and some college edu-
cation: OR, 1.36 [95% CI, 1.02-1.81]) and mortality 
risk (≤high school diploma: OR, 1.86; 95% CI, 1.18-
2.93) compared with having ≥college degree. The odds 
of overestimating recurrence risk were found to be 
greater among Hispanic patients (OR, 1.44; 95% CI, 
1.02-2.03) compared with their  white counterparts. 
Sensitivity analysis excluding patients who self-reported 
persistent or recurrent thyroid cancer or an unknown dis-
ease status on the patient survey (new total analytic cohort 
of 1422 patients) yielded similar results, with a lower ed-
ucational level associated with the overestimation of both 
risk of recurrence (≤high school diploma: OR, 1.60 [95% 
CI, 1.10-2.34]; and some college education: OR, 1.57 
TABLE 1. Distribution of Patient Demographics, 
Tumor Characteristics, and Risk Perception of the 
Analytic Sample (N = 1597)














Highest level of education  
≤High school diploma 362 (23.0)
Some college 488 (31.1)
≥College degree 719 (45.9)





Overestimate 10-y recurrence risk 354 (24.7)
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[95% CI, 1.15-2.14]) and mortality risk (≤high school 
diploma: OR, 1.74; 95% CI, 1.04-2.91) compared with 
having ≥college degree. Similarly, when we restricted the 
cohort to patients who had undergone both a total thy-
roidectomy and radioactive iodine ablation (new  total 
analytic cohort of 585 patients), a lower educational level 
again was found to be associated with overestimating 
recurrence risk (≤high school diploma: OR, 2.06 [95% 
CI, 1.19-3.57]; and some college education: OR, 1.67 
[95% CI, 1.03-2.70]) and mortality risk (≤high school 
diploma: OR, 2.49 [95% CI, 1.15-5.42]; and some col-
lege education: OR, 2.07 [95% CI, 1.05-4.04]) compared 
with having ≥college degree. However, in both sensitivity 
analyses, Hispanic ethnicity was no longer found to be 
associated with overestimation of recurrence risk.
Figure 4 shows the distribution of worry regarding 
disease recurrence and death from thyroid cancer relative 
to patient perception of recurrence and mortality risks. 
Worry about recurrence (62.0% vs 30.8%; P < .001) and 
death (43.0% vs 19.0%; P  <  .001) was greater among 
those who overestimated their risks of recurrence and 
mortality, respectively, compared with those who had a 
reasonably accurate risk estimate. Sensitivity analysis with 
patient-reported “worry” defined as any worry yielded 
similar results, with greater worry regarding disease recur-
rence (79.5% vs 55.5%; P < .001) and death (59.6% vs 
36.8%; P < .001) noted among those who overestimated 
their risk of recurrence and mortality risk, respectively, 
compared with those who had a reasonably accurate 
risk estimate. Similarly, when we excluded patients who 
self-reported a history of depression (new total analytic 
cohort of 1275 patients), there still was greater worry 
regarding recurrence (62.4% vs 29.3%; P  <  .001) and 
death (44.6% vs 18.1%; P < .001) noted among patients 
who overestimated their risk of recurrence and mortality 
risk, respectively, compared with patients with reasonably 
accurate risk estimates.
Figure 5 illustrates physical and mental QOL by 
patient perception of recurrence and mortality risks. 
Compared with the 2000 general US population, a lower 
Figure 2. Multivariable adjusted odds ratios (ORs) and 95% CIs of characteristics associated with overestimation of recurrence risk. 
SEER indicates Surveillance, Epidemiology, and End Results program.
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Figure 3. Multivariable adjusted odds ratios (ORs) and 95% CIs of characteristics associated with overestimation of mortality risk. 
SEER indicates Surveillance, Epidemiology, and End Results program.
Figure 4. Patient-reported worry regarding disease recurrence and death from thyroid cancer relative to patient perception of 
recurrence and mortality risks, respectively. Rao-Scott adjusted chi-square P values were <.001.
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mean physical QOL T score among patients who over-
estimated their mortality risk met the criteria for mean-
ingful change (mean T score, 43.1; 95% CI, 41.6-44.7). 
Mean physical and mental QOL T scores in patients 
who overestimated their recurrence risk or who had rea-
sonably accurate risk estimates did not meet the criteria 
for a meaningful change compared with the general US 
population. Furthermore, when compared with patients 
with reasonably accurate risk estimates, those who over-
estimated their recurrence risk were more likely to have 
low physical (36.9% with at least 1 SD below the mean 
vs 19.3%; P < .001) and mental (28.1% with at least 1 
SD below the mean vs 17.3%; P < .001) QOL T scores. 
Similarly, those who overestimated mortality risk also 
were more likely to have low physical (43.6% with at least 
1 SD below the mean vs 21.0%; P <  .001) and mental 
Figure 5. Physical and mental quality of life (QOL) by patient perception of disease recurrence and mortality risks. Lower T scores 
indicated a worse QOL. The mean T scores and 95% CIs were compared with those for the 2000 general US population. A meaningful 
change was defined as a minimal difference of 5 points compared with the mean T score of 50 for the general population.
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(31.5% with at least 1 SD below the mean vs 18.2%; 
P < .001) QOL T scores. In sensitivity analysis excluding 
patients who self-reported a history of depression (new 
total analytic cohort of 1275 patients), the mean physical 
QOL T score in patients who overestimated their mortal-
ity risk was 44.9 (95% CI, 43.2-46.6). Because a T score 
of 45.0 is within the 95% CI, this was no longer statis-
tically significantly different from that of the general US 
population.
DISCUSSION
The current large, population-based study has provided 
novel insights regarding risk perception among patients 
with low-risk thyroid cancer. Survivors who were less edu-
cated and those of Hispanic ethnicity were more likely to 
overestimate their recurrence risk, with the former also 
more likely to overestimate their mortality risk. These 
inaccurate risk perceptions were associated with increased 
worry regarding disease recurrence and death, respec-
tively, and decreased physical QOL among those who 
overestimated their mortality risk.
It is plausible that the association between lower 
educational level and overestimation of recurrence and 
mortality risks is secondary to lower health literacy and 
numeracy. In a study of women attending a high-risk 
family history clinic, Rutherford et al demonstrated a 
correlation between the educational level attained and 
health literacy, and a correlation between low health liter-
acy and an inaccurate risk perception of developing breast 
cancer.24 Moreover, Lipkus et al demonstrated that breast 
cancer patients with greater numeracy were more likely 
to provide estimates of cancer-free survival that matched 
estimates provided by a decision aid program for differ-
ent treatment options compared with patients with lower 
numeracy.25
The greater likelihood of overestimating recurrence 
risk among Hispanic patients may be due in part to phy-
sician-patient communication barriers or differences in 
acculturation, 2 topics that to the best of our knowledge 
remain largely unexplored in patients with thyroid cancer. 
Alternatively, it may be related to differential access to and 
quality of thyroid cancer care for Hispanic patients com-
pared with their white counterparts, with the potential for 
true differences in health outcomes.26-28
Worry regarding disease recurrence and death is 
common among patients with thyroid cancer.5,6 However, 
to the best of our knowledge, there is a lack of data regard-
ing the relationship between risk estimation and worry 
in survivors of thyroid cancer. Consistent with studies in 
the breast cancer literature, we found that patients who 
overestimated their risks of recurrence and mortality were 
more likely to report cancer-related worry.19,29,30 In addi-
tion, Papaleontiou et al demonstrated that in a cohort of 
patients with DTC, a lower educational level was associ-
ated with more worry about recurrence and death from 
thyroid cancer, and Hispanic patients were more worried 
about death compared with their white counterparts 2 
to 4  years after diagnosis.5 Despite the observed cross- 
sectional association between recurrence and mortality 
risk overestimation and cancer-related worry, with both 
more likely to occur among less educated and/or Hispanic 
patients, to our knowledge the causality between these 2 
variables remains unknown. Risk overestimation leading 
to increased cancer-related worry is as conceivable as is 
increased worry leading patients to report higher risk 
estimates. Further research is needed to elucidate the rela-
tionship between risk estimates and worry.
The findings of the current study have provided 
new insights into the relationship between thyroid can-
cer survivorship and QOL. Although QOL is an import-
ant area of research, prior studies have been discordant 
regarding the association between thyroid cancer history 
and QOL.6-8 In our analytic sample, only patients who 
overestimated their mortality risk demonstrated a mean-
ingful decrease in physical QOL compared with the 
general population, although the decrease was no longer 
statistically significantly different from that of the gen-
eral US population when we excluded patients who self- 
reported a history of depression. This suggests that a better 
understanding of risk perception is an important aspect of 
helping to understand QOL among survivors of thyroid 
cancer.
A major strength of the current study was the com-
bination of clinical cancer data from the SEER registries 
and a complementary patient survey, which provided 
granular details regarding patient report of risk estima-
tion, worry, and QOL. Collaboration with the Georgia 
and Los Angeles County SEER sites provided for a large 
and diverse population-based cohort of low-risk thyroid 
cancer survivors with adequate representation of Hispanic 
and black patients. Additional strengths of the current 
study included a high response rate among surveyed 
patients, a focus on an understudied cancer, and the use of 
the validated PROMIS scale to assess physical and mental 
QOL. The multiple sensitivity analyses performed were 
another strength of the study, although the new cohorts 
were smaller and therefore it is unclear whether some of 
the subsequent results were no longer statistically signifi-
cant due to the exclusion of a specific variable or due to a 
smaller cohort size.
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Some potential limitations should be noted. First, 
because the current study was cross-sectional, the observed 
associations do not suggest causation. Second, although 
mortality data were straightforward, patient-reported risk 
of thyroid “cancer recurrence” was compared with data 
regarding clinically determined risk of persistent structural 
or recurrent thyroid cancer. We did not distinguish bio-
chemical versus structural recurrent or persistent disease in 
the questionnaire, largely because although patients likely 
will recall being told their cancer is cured, recurred, or still 
present, they may not be able to differentiate biochemical 
versus structural recurrence. However, we did add sensitiv-
ity analyses to assess the translatability of findings in more 
specific cohorts. Third, the cohort included only patients 
from 2 geographic areas and therefore may not be repre-
sentative of all patients with thyroid cancer. However, the 
population covered by SEER is comparable to the gen-
eral US population. Fourth, patients were not asked about 
resources they used to learn about thyroid cancer or their 
comfort in communicating with physicians, both of which 
may influence their risk perception. Furthermore, the sur-
vey did not assess health literacy and numeracy or evalu-
ate acculturation among Hispanic patients, information 
that could provide insight into risk overestimation among 
patients who are less educated and Hispanic patients.
The study implications are relevant to patients and 
physicians. Despite the favorable prognosis of low-risk 
thyroid cancer, many vulnerable patients, including those 
with a lower educational level and Hispanic ethnicity, 
inaccurately perceived their risk of disease recurrence and/
or death, reported more worry, and experienced decreased 
physical QOL. Patient education that is appropriate for 
individuals of varying educational levels and culturally 
sensitive, and improved risk communication by physi-
cians, are necessary to address inaccurate risk perceptions. 
Improving psychosocial support, including the availabil-
ity of online websites and in-person support groups, for 
patients with thyroid cancer–related worry also is imper-
ative. Effective communication and appropriate reassur-
ance by physicians may help patients to create a framework 
for understanding their cancer prognosis so that they 
can make informed treatment decisions and adequately 
cope with the psychosocial stress related to having a can-
cer diagnosis. Such interventions may translate into an 
improved QOL for survivors of thyroid cancer.
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